Graviti Pharmaceuticals
Graviti Pharma is a research-driven pharmaceutical company committed to innovation, quality, and global healthcare solutions. With a focus on high standards, regulatory compliance, and cutting-edge research, it aims to deliver affordable, high-quality medicines worldwide. The company has a strong legacy of trust, continuous growth, and a vision to shape the future of medicine through biologics, precision medicine, and sustainable practices.
Industries
Nr. of Employees
large (251-1000)
Graviti Pharmaceuticals
KV Towers, 4th Floor, Jubilee Enclave, HITEC City, Hyderabad, Telangana 500081
Products
Atorvastatin (atorvastatin formulations)
Oral cardiovascular lipid‑lowering formulations (atorvastatin) available across multiple strengths and combination variants.
Cilnidipine (cilnidipine formulations)
Oral antihypertensive formulations containing cilnidipine across marketed strengths.
Rosuvastatin (rosuvastatin formulations)
Oral lipid‑lowering formulations (rosuvastatin) including single agents and combination variants.
Telmisartan (telmisartan formulations)
Oral antihypertensive formulations including single and fixed‑dose combination products with other antihypertensive agents.
Bisoprolol (bisoprolol formulations)
Oral beta‑blocker formulations for cardiovascular indications available in standard strengths and some combination forms.
Dapagliflozin (dapagliflozin formulations)
Oral SGLT2 inhibitor formulations for diabetes management available as single agents and in fixed‑dose combinations with metformin or glimepiride.
Atorvastatin (atorvastatin formulations)
Oral cardiovascular lipid‑lowering formulations (atorvastatin) available across multiple strengths and combination variants.
Cilnidipine (cilnidipine formulations)
Oral antihypertensive formulations containing cilnidipine across marketed strengths.
Rosuvastatin (rosuvastatin formulations)
Oral lipid‑lowering formulations (rosuvastatin) including single agents and combination variants.
Telmisartan (telmisartan formulations)
Oral antihypertensive formulations including single and fixed‑dose combination products with other antihypertensive agents.
Bisoprolol (bisoprolol formulations)
Oral beta‑blocker formulations for cardiovascular indications available in standard strengths and some combination forms.
Dapagliflozin (dapagliflozin formulations)
Oral SGLT2 inhibitor formulations for diabetes management available as single agents and in fixed‑dose combinations with metformin or glimepiride.
Services
On‑site manufacturing and packaging of oral solid dosage products under cGMP for export to regulated markets with regulatory documentation support.
Manufacture and go‑to‑market of branded generic pharmaceuticals for the domestic market, supported by field force and marketing.
Quality control testing, stability studies and validated analytical method execution for raw materials, in‑process and finished products.
Support for preparation and submission of regulatory dossiers and inspection readiness for international filings and audits.
On‑site manufacturing and packaging of oral solid dosage products under cGMP for export to regulated markets with regulatory documentation support.
Manufacture and go‑to‑market of branded generic pharmaceuticals for the domestic market, supported by field force and marketing.
Quality control testing, stability studies and validated analytical method execution for raw materials, in‑process and finished products.
Support for preparation and submission of regulatory dossiers and inspection readiness for international filings and audits.
Expertise Areas
- Oral solid dosage formulation and manufacturing
- Modified‑release and specialty formulation development
- Analytical chemistry and QC/testing
- Process validation and equipment qualification
Key Technologies
- High‑performance liquid chromatography (HPLC)
- Gas chromatography (GC)
- FTIR spectroscopy
- Atomic absorption spectrophotometry (AAS)
News & Updates
Regulatory Achievements
Successful USFDA audits with zero 483 observations, demonstrating compliance and operational excellence.
Expansion and Growth
Expansion of manufacturing capacity, entry into new therapeutic segments, and strengthening of global regulatory presence.
Company Legacy and Vision
From its inception in 2014 to becoming a global pharmaceutical powerhouse, Graviti Pharma's journey is marked by innovation, quality, and a focus on patient-centric solutions.
Future Focus Areas
Investments in biologics, biosimilars, precision medicine, and sustainable practices to shape the future of healthcare.
Global Regulatory Compliance
Manufacturing in facilities compliant with USFDA, WHO-GMP, and other standards, ensuring safety and efficacy.
Industry Recognition
Recognition for quality manufacturing, regulatory excellence, and innovation in pharmaceutical development.
Regulatory Achievements
Successful USFDA audits with zero 483 observations, demonstrating compliance and operational excellence.
Expansion and Growth
Expansion of manufacturing capacity, entry into new therapeutic segments, and strengthening of global regulatory presence.
Company Legacy and Vision
From its inception in 2014 to becoming a global pharmaceutical powerhouse, Graviti Pharma's journey is marked by innovation, quality, and a focus on patient-centric solutions.
Future Focus Areas
Investments in biologics, biosimilars, precision medicine, and sustainable practices to shape the future of healthcare.
Global Regulatory Compliance
Manufacturing in facilities compliant with USFDA, WHO-GMP, and other standards, ensuring safety and efficacy.
Industry Recognition
Recognition for quality manufacturing, regulatory excellence, and innovation in pharmaceutical development.